Novartis breaks ground on flagship manufacturing hub in North Carolina

East Hanover, December 12, 2025 – Novartis, a leading global innovative medicines company, broke ground yesterday on its more than 700,000-square-foot flagship manufacturing hub in North Carolina, moving rapidly to construct its recently announced investment in the state.

GlobeNewsWire • Dec 12, 2025

Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) on Monday presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated chronic myeloid leukemia (CML) patients at the American Society of Hematology Annual Meeting and Exposition.

Benzinga • Dec 9, 2025

Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder

Novartis AG (NYSE: NVS) on Tuesday shared results from the VAYHIT2 Phase 3 trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.

Benzinga • Dec 9, 2025

Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases

LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms of the agreement, Relation will receive $55 million, comprising an upfront payment, equity investment and additional R&D funding.

GlobeNewsWire • Dec 9, 2025

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

Basel, December 9, 2025 – Novartis today announced results showing that one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) remained progression-free for four or more years following treatment with Kisqali® (ribociclib) plus endocrine therapy (ET)1. Results were from a pooled, post-hoc exploratory analysis of first-line patients in the MONALEESA trials and will be presented at the 2025 San Antonio Breast Cancer Symposium® (SABCS) on December 11, 2025.

GlobeNewsWire • Dec 9, 2025

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Basel, December 9, 2025 – Novartis today announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1 -3. Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45%, based on the primary endpoint of time to treatment failure (TTF), which assesses how long patients maintain safe platelet levels during and after the treatment period1 ,2. The median time to treatment failure for patients receiving ianalumab plus eltrombopag was 2.8 times longer than those on placebo plus eltrombopag (13.0 months vs. 4.7 months)1 ,2. Detailed data will be presented during the Late-Breaking Abstract Session at the 67th American Society of Hematology Annual Meeting & Exposition (ASH) and simultaneously published in The New England Journal of Medicine 1, 2. “Treatments for ITP have historically focused on raising platelet counts, often requiring chronic therapy to control ITP. This means many patients remain on treatment long-term, facing persistent disease burden and symptoms like fatigue,” said Hanny Al-Samkari, M.D., Peggy S. Blitz Endowed Chair in Hematology/Oncology, Mass General Brigham, and Associate Professor of Medicine, Harvard Medical School. “The VAYHIT2 trial results are encouraging, as they demonstrated improved disease control even while patients spend time off treatment, pointing toward possible progress for people living with ITP.” Patients receiving ianalumab (9 mg/kg) plus eltrombopag also achieved a significantly higher rate of sustained platelet count improvement at six months versus placebo plus eltrombopag (62% vs. 39%), meeting the key secondary endpoint1 ,2. Fatigue improvement, as measured by PROMIS Fatigue, showed a mean reduction of 7.7 points with ianalumab plus eltrombopag versus 3.6 points with placebo plus eltrombopag1 ,2. “B cells drive the autoimmune response that leads to platelet destruction and increased bleeding risk in ITP. The novel dual mechanism of action of ianalumab aims to deplete B cells while blocking their survival signals,” said Mark Rutstein, M.D., Global Head, Oncology Development, Novartis. “Guided by our decades-long experience advancing ITP care, the VAYHIT2 findings underscore the potential of ianalumab to deliver durable control with a short course of four once-monthly doses, offering patients the possibility of achieving disease stability without ongoing treatment.” Two doses of ianalumab were assessed in VAYHIT2 with ianalumab 9 mg/kg demonstrating statistically significant improvements across both the primary and key secondary endpoints, and ianalumab 3 mg/kg demonstrating statistically significant improvements in the primary endpoint and numerical improvements in the key secondary endpoint1 -3.

GlobeNewsWire • Dec 9, 2025

Here's Why Novartis (NVS) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Dec 3, 2025

Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript

Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript

Seeking Alpha • Dec 1, 2025

Here's Why Novartis (NVS) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Nov 27, 2025

Novartis plans to cut up to 550 jobs at Swiss facility

Novartis said on Tuesday up to 550 full-time jobs could be cut by the end of 2027 at the Swiss pharmaceutical company's Stein facility near Basel in northern Switzerland.

Reuters • Nov 25, 2025